Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $144,375 - $187,941
-8,443 Reduced 52.76%
7,561 $163,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $172,240 - $503,661
10,283 Added 179.74%
16,004 $329,000
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $232,558 - $340,628
5,721 New
5,721 $269,000
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $160,446 - $219,741
-2,271 Reduced 39.59%
3,465 $259,000
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $24,450 - $72,219
935 Added 19.48%
5,736 $165,000
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $306,533 - $415,062
2,185 Added 83.52%
4,801 $674,000
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $412,935 - $478,963
2,616 New
2,616 $479,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.